{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"Percentage of participants alive at 24 months","groups":[{"description":"Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on day 0. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\nCliniMACS","id":"OG000","title":"Bulk SCT"},{"description":"Patients receive reduced intensity or myeloablative conditioning regimen, GVHD prophylaxis, and undergo T cell depleted or no T cell depleted allogeneic SCT on days 0, 2, 4, and 6. After completion of study treatment, patients are followed up every 6-8 weeks for up to 24 months\n\nallogeneic hematopoietic stem cell transplantation: Undergo allogeneic hematopoietic stem cell transplant\n\nCliniMACS","id":"OG001","title":"Fractionated SCT"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 months","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"% of participants alive"}